Medical expert of the article
New publications
Preparations
Inoculation against hemophilia infection
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Haemophilus influenzae type b (Hib) is a common causative agent of severe infections, mainly in children under 6 years old. In Russia and Ukraine Hib-infection has been registered since 2007, but the number of reports about it is insignificant, primarily due to special requirements for microbiological diagnosis. Mortality in Hib-meningitis reaches 15-20%, in 35% persistent CNS defects develop. Of complicated pneumonia, hemophilic infection causes 10-24%, among epiglottitis - more than 50%. Hemophilic infection in children also causes cellulitis, septic arthritis, osteomyelitis, endocarditis.
Vaccination against hemophilia is recommended in all national calendars. WHO notes that "a lack of data on morbidity should not be a reason for delaying the introduction of Hib vaccines." Vaccination of hemophilic infection is carried out in 170 countries, virtually eliminating meningitis and bacteremia caused by hemophilic infection, reduced the incidence of severe pneumonia by 20% (in Chile from 5.0 to 3.9 per 1000). Hib vaccination is recommended by the Ministry of Health of the Russian Federation, where there are opportunities for this. In Europe, WHO in 1998 aimed to "reduce by 2010 or earlier the frequency of infection caused by a haemophilus influenzae type b in the region to <1 per 100 000 population."
Hib vaccines registered in Russia
| Vaccine | Composition |
| Hemophilus type b conjugated dry vaccine - Russia, Rostov-Don | In 1 dose (0.5 ml) 10 μg capsular polysaccharide H. Influenzae b, 20 μg tetanus toxoid. Stabilizer - sucrose 50 mg. |
| Act-Hib - sanofi pasteur, France | In 1 dose (0.5 ml) 10 μg capsular polysaccharide H. Influenzae b, conjugated with tetanus toxoid. Preservative and antibiotic free |
| HYBERICS - Glaxo SmithCain, England | In 1 dose (0.5 ml) 10 μg of H. Influenzae type b polysaccharide conjugated with tetanus toxoid (30 μg). Preservative and antibiotic free |
| Kimne-Hib - Eber Biotech, Cuba (located on registration) | In 1 dose (0.5 ml) 10 μg of synthetic oligosaccharides conjugated with tetanus toxoid (26 μg) - fragments of the H. Influenzae capsule polysaccharide b. Contains 0.025 mg of the merthiolate, phosphate buffer |
[Vaccination against hemophilia: Hib vaccine
In Russia, 3 Hib vaccines have been registered, in the phase of registration there is a Cuban vaccine. The hib component is also contained in Pentaxim.
Vaccination against hemophilia is carried out at the age of 3 months. Three times together with DTP, HBV and IPV (to be administered separately, but Hibericks can be administered in a single syringe with Infanriks), revaccination after 12 months. After the 3rd vaccination. At the beginning of vaccination at the age of 6-12 months. 2 doses are sufficient with an interval of 1-2 months. With a revaccination at 18 months, at the age of 1-5 years, 1 injection is enough. Tetanus toxoid, which is a protein conjugate in Hib vaccines, does not create immunity to tetanus. Preventive efficacy 95-100%. Protective titers of antibodies are conserved for at least 4 years.
Vaccination reactions and contraindications
Reactions weak: hyperemia and compaction (<10% of grafted), temperature> 38.0 ° (1%). Complications are extremely rare, 4 cases of Guillain-Barre syndrome are described, of which 1 child received DTP. Vaccines do not have special contraindications.
Contraindication to the vaccination against haemophilus infection is hypersensitivity to the components of the vaccine, especially to tetanus toxoid, as well as a strong reaction to the previous administration. HIV infection is not a contraindication to the introduction of the Hib vaccine.
Attention!
To simplify the perception of information, this instruction for use of the drug "Inoculation against hemophilia infection" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.